Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at ZAR 1.41T, ahead of Gilead Sciences (ZAR 626.2B) and Biogen (ZAR 192.4B). Figures as of 18 Nov 2026, 14:03 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenZAR 1.41T
- Median
- ZAR 12.1B
- Combined market value
- ZAR 14.61T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | ZAR 1.41T | ZAR 4.26T | ZAR 7,877.13 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | ZAR 626.2B | ZAR 3.63T | ZAR 2,928.74 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | ZAR 192.4B | ZAR 637.7B | ZAR 4,313.99 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | ZAR 63.4B | ZAR 1.44T | ZAR 3,557.29 | 3.93% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | ZAR 52.8B | ZAR 361.9B | ZAR 1,459.73 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | ZAR 43.1B | ZAR 176.7B | ZAR 855.78 | 0.12% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | ZAR 42.6B | ZAR 188.2B | ZAR 1,650.84 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | ZAR 23.7B | ZAR 288.9B | ZAR 2,854.09 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | ZAR 23.4B | ZAR 1.02T | ZAR 16,298.86 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | ZAR 17.2B | ZAR 114.6B | ZAR 107.68 | 4.68% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | ZAR 14.5B | ZAR 178.3B | ZAR 2,789.76 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | ZAR 12.4B | ZAR 605.3B | ZAR 2,798.53 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | ZAR 11.8B | ZAR 287.5B | ZAR 1,178.31 | 2.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | ZAR 8.2B | ZAR 196.3B | ZAR 1,249.35 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | ZAR 5.9B | ZAR 67B | ZAR 690.64 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | ZAR 5.5B | ZAR 161.7B | ZAR 1,021.78 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | ZAR 4.9B | ZAR 79.3B | ZAR 490.07 | 2.22% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | ZAR 3.3B | ZAR 108.9B | ZAR 1,665.11 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | ZAR 2.9B | ZAR 131.4B | ZAR 1,926.58 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | ZAR 2.8B | ZAR 178.5B | ZAR 2,090.34 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | ZAR 2.7B | ZAR 94.6B | ZAR 775.45 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | ZAR 2B | ZAR 152.2B | ZAR 5,135.54 | 0.22% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | ZAR 1.8B | ZAR 118.2B | ZAR 571.27 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | ZAR 670.7M | ZAR 121.3B | ZAR 1,357.89 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2016 ZAR).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (ZAR 1.41T), Gilead Sciences (ZAR 626.2B) and Biogen (ZAR 192.4B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:03 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of ZAR 14.61T as of 18 Nov 2026, 14:03 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.